A Qualitative Study on Patients' (un)Ability and (un)Willingness to Use Telemonitoring in Inflammatory Bowel Diseases
Launched by FRANCISCUS GASTHUIS · Nov 6, 2023
Trial Information
Current as of November 13, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how and why some patients with Inflammatory Bowel Diseases (IBD) might have difficulty or choose not to use a telemonitoring app called IBD Care Everywhere. The study aims to understand the factors that influence patients' willingness and ability to use this technology, which could help improve their care. Researchers will conduct interviews with patients to gather information about their experiences and preferences, focusing on those who are both interested in and hesitant to use telemonitoring. The goal is to identify ways to better support patients in making informed choices about their healthcare options.
To participate in this study, individuals must be over 18 years old with a confirmed diagnosis of IBD, and they should be in stable remission, meaning their symptoms are currently well-managed. Some specific health criteria must also be met, such as not having had any medication changes in the past three months. The study is not yet recruiting participants, but once it begins, selected patients will share their thoughts and experiences through interviews. This research is important because it could help healthcare providers understand patient needs and improve access to telehealth services, ensuring that everyone can receive the best possible care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged \>18 years
- • A confirmed IBD-diagnosis according to current guidelines
- • Maintenance therapy with no medication changes in the last three months
- * Remission:
- • Crohn's disease: Faecal calprotectin (FCP) \< 100 µ g/g and Harvey Bradshaw Index (HBI) \< 5
- • Ulcerative Colitis: Faecal calprotectin (FCP) \< 250 µ g/g and Simple Clinical Colitis Activity Index scores (SCCAI) \< 3
- Exclusion Criteria:
- • Presence of a stoma
- • Presence of an ileo-anal pouch or ileorectal anastomosis
About Franciscus Gasthuis
Franciscus Gasthuis is a leading healthcare institution based in the Netherlands, renowned for its commitment to high-quality patient care and innovative medical research. As a clinical trial sponsor, Franciscus Gasthuis focuses on advancing medical knowledge and treatment options across various specialties through rigorous clinical studies. The institution prioritizes ethical standards, patient safety, and scientific integrity, collaborating with a multidisciplinary team of healthcare professionals and researchers to contribute to the development of cutting-edge therapies and improve health outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported